Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Neues US-Patent für RegenLab
  • USA - español
  • USA - Français
  • Middle East - English
  • Middle East - English
  • USA - English

Regen Lab SA Logo (PRNewsfoto/Regen Lab SA)

News provided by

Regen Lab SA

May 23, 2019, 12:58 ET

Share this article

Share toX

Share this article

Share toX

LE-MONT-SUR LAUSANNE, Schweiz, 23. Mai 2019 /PRNewswire/ -- Antoine Turzi, Erfinder, Regen Lab SA und RegenLab USA LLC freuen sich bekannt geben zu können, dass das United States Patent and Trademark Office (USPTO) zwei neue US-Patente vergeben hat, die seine Technologien Thrombin Serum (TS), Platelet Rich Plasma (PRP) und Hyaluronic Acid (HA) abdecken:

i) Systeme/Methoden für die Präparation von PRP und HA in einem einzigen All-in-One-Gerät – die Technologie CELLULAR MATRIX™*, mit Röhrchen, die HA, ein thixotropes Gel und ein Antikoagulans enthalten: U.S. Patent No. 10,272,139 und

Continue Reading
Patent document (PRNewsfoto/Regen Lab SA)
Patent document (PRNewsfoto/Regen Lab SA)
Patent document (PRNewsfoto/Regen Lab SA)
Patent document (PRNewsfoto/Regen Lab SA)
Patent certificate (PRNewsfoto/Regen Lab SA)
Patent certificate (PRNewsfoto/Regen Lab SA)

ii) Systeme für die Präparation von Thrombin-Serum und biologischem Klebstoff, insbesondere Röhrchen, die ein thixotropes Gel enthalten: U.S. Patent No. 10,226,516.

Diese neuen Patente stellen eine Anerkennung durch die USPTO für die Innovation, Technologie und Wirksamkeit von RegenLab dar. Das sind großartige Neuigkeiten für RegenLab, seine Mitarbeiter und Partner, und sie rechtfertigen die Investition von RegenLab in Forschung und Entwicklung sowie die Durchsetzung seiner geistigen Eigentumsrechte.

Damit beläuft sich die Anzahl erteilter US-Patente auf diese Technologien auf 10 (zehn) und erweitert das Talentportfolio von RegenLab zusammen mit vor kurzem gewährten Patenten in anderen Jurisdiktionen:

i)  Methoden für die Präparation von PRP durch die Zentrifugierung von Röhrchen mit einem (polymerischen) thixotropen Gel (plus Antikoagulans) und die Entfernung von Platelet Poor Plasma (PPP), optional in Kombination mit einem Zellextrakt oder Koagulationsaktivator: US10,092,598

ii) Methoden für die Präparation von PRP durch die Zentrifugierung von Röhrchen mit nur einem thixotropen Gel und einem Koagulans, optional in Kombination etwa mit Koagulationsaktivator, Zellextrakt, Creme, Füllstoff, Hydrogel, Vitamin, Schmerzlinderungsmittel, Analgetikum oder HA: US10,080,770

iii) Systeme für die Präparation von PRP und Knochenmarkkonzentrat (BMC), insbesondere Röhrchen mit einem thixotropen Gel und einem Antikoagulans: US10,064,894

iv) Systeme/Methoden, die PRP und HA in zwei separaten Geräten kombinieren: US10,052,349

v) Systeme/Methoden für die Präparation von PRP, insbesondere Röhrchen mit einem thixotropen Gel und Natriumzitrat: US9,833,478

vi) Zusammensetzung aus HA, Antikoagulans und thixotropem Gel, Röhrchen/Behälter mit einer solchen Zusammensetzung, Kombination mit Koagulansaktivator oder Zellextrakt: US9,517,255

vii) Methoden für die Präparation von HA und PRP in einem einzigen Gerät, insbesondere durch die Zentrifugierung von Röhrchen mit HA und optional ein Gel und Antikoagulans, optional in Kombination etwa mit einem Koagulansaktivator oder einem Zellextrakt: US8,945,537

viii) Spezifische PRP-Zusammensetzungen, Röhrchen, die spezifische thixotrope Gels und Antikoagulantien, kombiniert mit Zellextrakten, ähnlichen Methoden und Zellkultumethoden: US8,529,957.

PRP* ALLEIN

PRP+ ZELLKULTUR

ATS* ALLEIN + PRP

PRP + HA*

PRP + ZELLEXTRAKT

WO2011/110948

WO2008/023026

WO2011/110948

WO2011/110948

WO2008/023026

WO2013/061309

WO2011/110948

US10226516

WO2013/061309

WO2011/110948

WO2016/083549

WO2016/083549

AU2013203115B

WO2016/083549

WO2016/083549

US10092598

US8529957

JP6359495

US10272139

US10092598

US10080770

EP2073862B

EP3403659 angemeldet

US9517255

US10080770

US10064894

CH696752

JP2017149786

US8945537

US9517255

US9833478


CN105998067

US10052349

US8529957

US8529957


IL252122

EP3184114B

EP2073862B

EP2073862B


und CA2915649

EP2544697B1

CH696752

CH696752



CA2789533C


HK1231793



CN103079577B


Angemeldet



JP6076091


US2018353436



AU2011225828B


EP3111974 und



IL221133


EP3395383



RU2614722



RU2667964



JP6076091



JP6321119



KR20130067247



HK1179507



und angemeldet



US16/298,112



7167/DELNP/2012



JP2017149786



*PRP: Platelet Rich Plasma (thrombozytenreiches Plasma)

*HA: Hyaluronsäure

*ATS: Autologes Thrombin-Serum
CN105998067 US2018327120 und EP2771241

Über RegenLab

RegenLab ist ein führender Innovator von medizinischen Geräten zur Präparation von thrombozytenreichem Plasma, die es unter den bekannten Marken REGENLAB®, REGENKIT® und CELLULAR MATRIX™* vermarktet.

RegenLab ist darüber hinaus bestrebt, pyrogenfreie Geräte von höchster Qualität und Sicherheit zu liefern sowie Kunden über die Durchsetzung seiner geistigen Eigentumsrechte zu schützen.

Weitere Informationen über RegenLabs und seine Patente finden Sie unter https://www.regenlab.com/corporate/ patentsund https://www.regenlabusa.com.

* Nur erhältlich für Forschungszwecke in den USA (nicht zum Verkauf)

RegenLab® USA LLC 575 Madison Avenue
Suite 1006 New York, NY 10022-2511 Telefon & Fax: 1-800-220-9082
www.regenlabusa.com

Regen Lab SA En Budron B2
CH - 1052 Le Mont-Sur-Lausanne
Schweiz                             
Tel. +41(0)21 864 01.11 
Fax. +41(0)21 864 01.10
www.regenlab.com

Roberta Ruggeri, Tel. +41(0)21 864 01.11

https://mma.prnewswire.com/media/890782/Patent_document_Infographic.jpg
https://mma.prnewswire.com/media/890783/Patent_document_Infographic.jpg
https://mma.prnewswire.com/media/890784/Patent_certificate_Infographic.jpg
Logo - https://mma.prnewswire.com/media/890785/Regen_Lab_SA_Logo.jpg    

Related Links

http://www.regenlab.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.